Clinical Trial Update: Real-World Joint Outcomes After Selective Transition to Low-Dose Emicizumab in Pediatric Hemophilia A [Phase 2, Phase 3]

View source ↗

Summary

An update on a pediatric Hemophilia A trial examining real-world joint outcomes after a selective transition to low-dose emicizumab. The study spans Phase 2 and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Emicizumab (emicizumab)

Snippet

Sponsor: Chulalongkorn University | Conditions: Hemophilia A Patient | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING